This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser.
Print Document
View Excel Document
Cover
Document And Entity Information
Financial Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements of Operations
Consolidated Statements of Comprehensive Earnings
Consolidated Statements of Equity
Consolidated Statements of Cash Flows
Notes to Financial Statements
Nature of Operations
Summary of Significant Accounting Policies
Acquisitions and Other Transactions
Revenue Recognition and Accounts Receivable
Balance Sheet Components
Equity Method Investments
Goodwill and Other Intangible Assets
Financial Instruments and Risk Management
Debt
Comprehensive Earnings
Income Taxes
Share-Based Incentive Plan
Employee Benefit Plans
Segment Information
Commitments
Subsidiary Guarantors
Restructuring
Collaboration and Licensing Agreements
Litigation
Other
Valuation and Qualifying Accounts
Accounting Policies
Summary of Significant Accounting Policies (Policies)
Notes Tables
Summary of Significant Accounting Policies (Tables)
Acquisitions and Other Transactions (Tables)
Revenue Recognition and Accounts Receivable (Tables)
Balance Sheet Components (Tables)
Equity Method Investments (Tables)
Goodwill and Other Intangible Assets (Tables)
Financial Instruments and Risk Management (Tables)
Debt (Tables)
Comprehensive Earnings (Tables)
Income Taxes (Tables)
Share-Based Incentive Plan (Tables)
Employee Benefit Plans (Tables)
Segment Information (Tables)
Commitments (Tables)
Subsidiary Guarantors (Tables)
Restructuring (Tables)
Notes Details
Nature of Operations (Narrative) (Details)
Summary of Significant Accounting Policies (Narrative) (Details)
Summary of Significant Accounting Policies (Basic And Diluted Earnings Per Ordinary Share Attributable To Mylan N.V.) (Details)
Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Adoption of ASU 2014-09) (Details)
Acquisitions and Other Transactions Acquisitions and Other Transactions (Apicore) (Narrative) (Details)
Revenue Recognition and Accounts Receivable Revenue Disaggregation (Details)
Acquisitions and Other Transactions Acquisitions and Other Transactions (Apicore Schedule of Purchase Price Allocation) (Details)
Revenue Recognition and Accounts Receivable (Narrative) (Details)
Acquisitions and Other Transactions (Meda) (Narrative) (Details)
Revenue Recognition and Accounts Receivable Variable Consideration (Details)
Acquisitions and Other Transactions (Meda Schedule of Purchase Price Allocation) (Details)
Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details)
Acquisitions and Other Transactions (Topicals Business) (Narrative) (Details)
Revenue Recognition and Accounts Receivable Variable Consideration Rollforward (Details)
Acquisitions and Other Transactions (Topicals Business Schedule of Purchase Price Allocation) (Details)
Acquisitions and Other Transactions (Jai Pharma Limited) (Narrative) (Details)
Acquisitions and Other Transactions (Jai Pharma Limited Schedule of Purchase Price Allocation) (Details)
Acquisitions and Other Transactions (Meda and EPD Business Pro Forma Financial Information) (Details)
Acquisitions and Other Transactions (EPD Business) (Narrative) (Details)
Acquisitions and Other Transactions (EPD Business Schedule of Purchase Price Allocation) (Details)
Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details)
Balance Sheet Components (Narrative) (Details)
Balance Sheet Components Balance Sheet Components (Cash and Cash Equivalents) (Details)
Balance Sheet Components (Accounts receivable, net) (Details)
Balance Sheet Components (Inventories) (Details)
Balance Sheet Components (Prepaids and other current assets) (Details)
Balance Sheet Components (Property, Plant and Equipment) (Details)
Balance Sheet Components (Other Assets) (Details)
Balance Sheet Components (Trade Accounts Payable) (Details)
Balance Sheet Components (Other Current Liabilities) (Details)
Balance Sheet Components (Other noncurrent liabilities) (Details)
Equity Method Investments (Narrative) (Details)
Equity Method Investments (Balance Sheet) (Details)
Equity Method Investments (Net Assets) (Details)
Equity Method Investments (Income Statement) (Details)
Goodwill and Other Intangible Assets (Narrative) (Details)
Goodwill and Other Intangible Assets (Changes in Carrying Amount Of Goodwill) (Details)
Goodwill and Other Intangible Assets (Components of Intangible Assets) (Details)
Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details)
Goodwill and Other Intangible Assets (Amortization Expense) (Details)
Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Future amortization expense) (Details)
Financial Instruments and Risk Management (Narrative) (Details)
Financial Instruments and Risk Management (Derivatives Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details)
Financial Instruments and Risk Management (Derivatives Not Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details)
Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details)
Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationship) (Details)
Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships) (Details)
Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details)
Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments) (Details)
Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details)
Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details)
Financial Instruments and Risk Management (Schedule of Available-for-sale Securities Reconciliation) (Details)
Financial Instruments and Risk Management (Maturities of Available-for-sale Debt Securities at Fair Value) (Details)
Debt (Short-term borrowings) (Details)
Debt Debt (Receivables Facility and Commercial Paper Program) (Details)
Debt (Summary of Long-term Debt) (Details)
Debt (Revolving Facilities and Term Facilities) (Details)
Debt (Issuance of 2018 Senior Notes) (Details)
Debt (Senior Notes) (Details)
Debt (Fair Value) (Narrative) (Details)
Debt (Minimum Repayments on Outstanding Borrowings) (Details)
Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details)
Comprehensive Earnings (Components of Other Comprehensive Loss) (Details)
Income Taxes (Narrative) (Details)
Income Taxes (Schedule of Components of Income Tax Provision) (Details)
Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)
Income Taxes (Statutory Tax Rate to Effective Tax Rate Reconciliation) (Details)
Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)
Share-Based Incentive Plan (Narrative) (Details)
Share-Based Incentive Plan (Stock Awards) (Details)
Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details)
Share-Based Incentive Plan (Valuation Assumptions) (Details)
Employee Benefit Plans (Narrative) (Details)
Employee Benefit Plans (Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost (Details)
Employee Benefit Plans (Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits) (Details)
Employee Benefit Plans (Net Periodic Benefit Costs) (Details)
Employee Benefit Plans (Changes in Projected Benefit Obligations, Plan Assets and Funded Status) (Details)
Employee Benefit Plans (Net Accrued Benefit Costs Classification on Balance Sheet) (Details)
Employee Benefit Plans (Plans with PBO in Excess of Plan Assets) (Details)
Employee Benefit Plans (Fair Values of Plan Assets) (Details)
Employee Benefit Plans (Weighted Average Assumptions) (Details)
Employee Benefit Plans (Effect of One Percentage Point Increase or Decrease in Health Care Cost Trend Rates) (Details)
Employee Benefit Plans (Estimated Future Benefit Payments) (Details)
Segment Information (Narrative) (Details)
Segment Information (Reconciliation of Segment Information to Total Consolidated Information) (Details)
Segment Information (Third Party Net Sales by Major Customers) (Details)
Segment Information (Net Third Party Sales Classified Based on Geographic Location of Entity) (Details)
Commitments (Narrative) (Details)
Commitments (Schedule of Operating Leases) (Details)
Subsidiary Guarantors (Narrative) (Details)
Subsidiary Guarantors Condensed Consolidating Balance Sheet (Details)
Subsidiary Guarantors Condensed Consolidating Statement of Operations (Details)
Subsidiary Guarantors Condensed Statement of Comprehensive Earnings (Details)
Subsidiary Guarantors Condensed Consolidating Statement of Cash Flows (Details)
Subsidiary Guarantors Schedule of Cash, Cash Equivalents and Restricted Cash (Details)
Restructuring (Narrative) (Details)
Collaboration and Licensing Agreements (Narrative) (Details)
Litigation (Lorazepam and Clorazepate) (Narrative) (Details)
Litigation (Pricing and Medicaid Litigation) (Narrative) (Details)
Litigation (Modafinil Antitrust Litigation and FTC Inquiry) (Narrative) (Details)
Litigation (Medicare Drug Rebate Program Settlement) (Details)
Litigation (Drug Pricing Matters) (Details)
Litigation (European Commission Proceedings) (Narrative) (Details)
Litigation (U.K. Competition and Markets Authority) (Narrative) (Details)
Litigation (Product Liability) (Narrative) (Details)
Litigation (Intellectual Property) (Narrative) (Details)
Litigation (Other Litigation) (Narrative) (Details)
Valuation and Qualifying Accounts (Details)
All Reports
Rendering Log